CEPHALEXIN-GA cefalexin 250mg (as monohydrate) capsule blister pack

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

cefalexin (Equivalent: cefalexin, Qty 250 mg)

Available from:

Medis Pharma Pty Ltd

INN (International Name):

cefalexin

Pharmaceutical form:

Capsule

Composition:

Excipient Ingredients: Gelatin; purified water; titanium dioxide; sunset yellow FCF; quinoline yellow aluminium lake; patent blue V; microcrystalline cellulose; sodium lauryl sulfate; magnesium stearate; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; Shellac; strong ammonia solution; iron oxide black; potassium hydroxide

Administration route:

Oral

Units in package:

20 capsules

Prescription type:

(S4) Prescription Only Medicine

Therapeutic indications:

Treatment of the following bacterial infections when caused by susceptible strains of the designated micro-organisms. Respiratory tract infections: Strep. pneumoniae and group A beta-haemolytic streptococci. Although penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections (including the prophylaxis of rheumatic fever), cephalexin is generally effective in the eradication of streptococci from the nasopharynx. Substantial data establishing the efficacy of cephalexin in the subsequent prevention of rheumatic fever are not available at present. Bacterial sinusitis: Streptococci, Strep. pneumoniae and Staph. aureus (methicillin sensitive only). Otitis media: Strep. pneumoniae, staphylococci (methicillin sensitive only). Skin and skin structure infections: Staphylococci (methicillin sensitive only) and/or streptococci. Genitourinary tract infections, including acute prostatitis: E. coli, P. mirabilis and Klebsiella sp. The effectiveness of cephalexin in the treatment of bacterial infections of the brain and spinal column has not been established and CEPHALEXIN-GA is not indicated in these conditions (see CONTRAINDICATIONS). Note: Appropriate culture and susceptibility tests should be initiated prior to and during therapy to determine susceptibility of the causative organism to CEPHALEXIN-GA. Renal function studies should be performed when indicated.

Product summary:

Visual Identification: Size '2' capsules with dark green cap imprinted with "250" in black ink and white body.; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 2 Years; Container Temperature: Store below 30 degrees Celsius

Authorization status:

Registered

Authorization date:

2008-06-24